Rossella Bruno
Michele Simbolo
Iacopo Petrini- 1Unit of Pathological Anatomy, University Hospital of Pisa, Pisa, Italy
- 2Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy
- 3Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
Editorial on the Research Topic
Primary and acquired resistance in lung cancer
Targeted therapies and immunotherapy have significantly enhanced treatment of patients with advanced and metastatic non-small cell lung cancer (NSCLC), which accounts for about 85% of all lung cancer cases (1). The molecular characterization of non-squamous tumors is necessary to identify patients harboring targetable alterations (2). Despite the continuous advances of precision medicine, primary and acquired drug resistance remains a challenge (2).
The articles featured in this Research Topic mainly focus on EGFR and KRAS addicted tumors, collectively accounting for approximately 45% of NSCLC. The authors describe resistance mechanisms to tyrosine-kinase inhibitors (TKIs) and immune-checkpoint inhibitors. Additionally, this Research Topic includes a study exploring the predictive role of genetic alterations in small cell lung cancer (SCLC).
In NSCLC, EGFR exhibits somatic mutations of the intracellular tyrosine-kinase domain mainly between exons 18-21. The majority of these mutations are predictive of TKI response, while a minority confers resistance to specific treatments (2). Resistance mechanisms vary depending on drugs and include on-target (secondary alterations within the same gene) and off-target mechanisms (alternative pathway activation, histological transformation). The acquisition of the T790M mutation within EGFR exon 20 is the most common resistance mechanism to first (gefitinib, erlotinib) and second-generation (afatinib) TKIs. Hsieh et al. reported a higher T790M mutation rate with first compared to second-generation TKIs. Tumors carrying T790M mutation respond to the third-generation EGFR inhibitor, osimertinib, which was initially approved for patients with this acquired resistance mechanism. Currently, osimertinib is the preferred drug for the first-line therapy of tumors with EGFR common activating mutations (3). There are not predominant resistance mutations for third-generation TKIs (4). Mahfoudhi et al. reviewed preclinical studies evaluating acquired resistance to third-generation EGFR TKIs across all treatment lines. Secondary EGFR mutations, like C797S, occur in approximately 10% of patients. In contrast, most tumors activate alternative pathways bypassing EGFR inhibition (i.e. MET amplification). Recent studies, as reported by Fabrizio et al., explored the influence of epigenetic alterations (DNA methylation and miRNA deregulation) on treatment resistance. There is an emerging evidence for a role of multi-gene and genome-wide global methylation profile, particularly when liquid biopsy is employed. In the same context, Lee et al. showed how platelet activation can confer acquired resistance to EGFR TKIs, thus suggesting new therapeutic strategies.
Mutations affecting KRAS gene are the most frequent in lung cancer, those specific to codon 12 are especially related to smokers. To date, only KRAS G12C inhibitors are approved for the second-line treatment of NSCLC patients who progress to a first-line immunotherapy or chemo-immunotherapy (2). KRAS inhibitors specific for G12D mutation are under evaluation in preliminary clinical trials (5). Therefore, the initial treatment for NSCLC patients carrying KRAS mutations is immunotherapy or chemo-immunotherapy, according to PD-L1 expression levels. Alternatively, chemotherapy is considered for patients with contraindication for immunotherapy. As described by Fancelli et al., different KRAS mutations have distinct characteristics and behaviors. Improved outcomes are observed with immunotherapy alone or in combination with chemotherapy when compared with chemotherapy alone, especially for mutations G12C, G12D and G12A, while a poorer prognosis is associated with G12V mutation. In clinical trials KRAS G12C inhibitors obtain objective responses between 30-50%, with a median progression free survival (PFS) of 5.6-6.5 months (6, 7). Resistance mechanisms to KRAS G12C inhibitors are poorly characterized. Ning et al. reviewed non-genetic mechanisms, including epithelial to mesenchymal transition, which are responsible of adaptive drug resistance and treatment failure. Considering the relative low response rate and PFS of KRAS inhibitors, identification of factors impacting response is crucial. Strategies promoting mesenchymal-to-epithelial transition, as well as the inhibition of YAP (oncoprotein acting downstream Hippo pathway) should be further investigated.
As mentioned before, immunotherapy is an important option for patients without targetable alterations (8) not only in the advanced settings, but also in early stages as neoadjuvant or adjuvant treatment (9). Neoadjuvant chemo-immunotherapy improved overall survival compared to chemotherapy in phase III clinical trials (10, 11). Alì et al. showed that neoadjuvant chemo-immunotherapy improved pathological responses compared to chemotherapy alone, and correlated with a better overall survival and event free survival in resectable NSCLC. However, a substantial percentage of patients do not respond to neoadjuvant chemo-immunotherapy. Consequently, there is an urgent need for predictive biomarkers. PD-L1, predictive of response for stage IV patients, has a limited utility in the neoadjuvant setting. In the same study authors observed that after chemo-immunotherapy residuals tumors showed enhanced expression levels of YAP/TAZ and CTLA4 genes opening new interesting scenarios.
When the first-line chemo-immunotherapy or immunotherapy alone fails, chemotherapy becomes the standard second-line option, but it is often associated with toxicity and limited effectiveness. The combination of anti-angiogenetic drugs with taxane has improved patients’ outcome: for example, the addition of ramucirumab to docetaxel slightly increased overall survival after progression to a first-line chemotherapy (12). The effect of this combination after immunotherapy remains poorly characterized. Nevertheless, in preclinical studies it has been demonstrated that anti-angiogenic drugs can modulate tumor microenvironment enhancing the activity of immune check-point inhibitors (13). Kareff et al. evaluated the use of ramucirumab and docetaxel following disease progression on chemotherapy and immunotherapy combination. Their data support the advantageous effect of a combined chemotherapy and anti-angiogenic therapy after first-line immunotherapy exposure.
Precision medicine perfectly suits NSCLC, whereas therapeutic options are still limited for SCLC (15% of all cases). SCLC patients typically achieve tumor shrinkage with the first-line of chemotherapy, but, thereafter, they often rapidly experience disease progression (14). SCLC genetic landscape could help to understand how to stratify tumors improving prognosis definition. In their study Tang et al. used whole exome sequencing data to identify significant genetic differences, developing a classifier capable of predicting chemoresistance, chemosensitivity, and the risk of recurrence in SCLC.
Comprehensive genome profiling is providing valuable insights into resistance mechanisms to lung cancer treatments. However, it is important to recognize that various resistance alterations can coexist within the same tumor or between primary tumors and metastatic sites. It is essential to thoroughly evaluate resistance at molecular levels to track the genetic evolution of cancer and optimize treatment.
Author contributions
RB: Writing – original draft, Writing – review & editing. MS: Writing – original draft, Writing – review & editing. IP: Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Acknowledgments
We acknowledge all the Authors who contributed to this Research Topic.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Villaruz LC, Socinski MA, Weiss J. Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine. Front Oncol (2023) 13:1124167. doi: 10.3389/fonc.2023.1124167
2. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol (2023) 34:339–57. doi: 10.1016/j.annonc.2022.12.009
3. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR -mutated advanced NSCLC. N Engl J Med (2020) 382:41–50. doi: 10.1056/NEJMoa1913662
4. Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer (2019) 121:725–37. doi: 10.1038/s41416-019-0573-8
5. Christensen JG, Hallin J. The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis. Nat Med (2022) 28:2017–8. doi: 10.1038/s41591-022-02008-6
6. de Langen AJ, Johnson ML, Mazieres J, Dingemans A-MC, Mountzios G, Pless M, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet (2023) 401:733–46. doi: 10.1016/S0140-6736(23)00221-0
7. Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou S-HI, Pacheco JM, et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med (2022) 387:120–31. doi: 10.1056/NEJMoa2204619
8. Gridelli C, Peters S, Mok T, Forde PM, Reck M, Attili I, et al. First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology. ESMO Open (2022) 7:100355. doi: 10.1016/j.esmoop.2021.100355
9. De Scordilli M, Michelotti A, Bertoli E, De Carlo E, Del Conte A, Bearz A. Targeted therapy and immunotherapy in early-stage non-small cell lung cancer: current evidence and ongoing trials. IJMS (2022) 23:7222. doi: 10.3390/ijms23137222
10. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee S-H, Gao S, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med (2023) 389:491–503. doi: 10.1056/NEJMoa2302983
11. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med (2022) 386:1973–85. doi: 10.1056/NEJMoa2202170
12. Garon EB, Ciuleanu T-E, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet (2014) 384:665–73. doi: 10.1016/S0140-6736(14)60845-X
13. Subramanian M, Kabir AU, Barisas D, Krchma K, Choi K. Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy. Cell Rep Med (2023) 4:100896. doi: 10.1016/j.xcrm.2022.100896
Keywords: lung cancer, targeted therapy, immunotherapy, predictive biomarkers, primary resistance, acquired resistance
Citation: Bruno R, Simbolo M and Petrini I (2023) Editorial: Primary and acquired resistance in lung cancer. Front. Oncol. 13:1310331. doi: 10.3389/fonc.2023.1310331
Received: 09 October 2023; Accepted: 12 October 2023;
Published: 01 November 2023.
Edited and Reviewed by:
Lizza E.L. Hendriks, Maastricht University Medical Centre, NetherlandsCopyright © 2023 Bruno, Simbolo and Petrini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Rossella Bruno, cm9zc2VsbGEuYnJ1bm9AZm9yLnVuaXBpLml0